Abstract:Introduction: Pulmonary arterial hypertension (PAH) is a disaster disease characterized by obliterative vascular remodeling and persistent increase of vascular resistance, leading to right heart failure and premature death. Understanding the cellular and molecular mechanisms will help develop novel therapeutic approaches for PAH patients. Hypothesis: Genetic SOX17 mutations are associated with PAH. We hypothesized that endothelial SOX17 mutations or loss of function contributes to endothelial dysfunction and the pathogenesis of PAH. Methods: Endothelial-specific deletion of Sox17 ( Sox17iCKO ) mice were generated. Sox17iCKO and Sox17f/f (WT) mice after tamoxifen injection were incubated without or with hypoxia (10% O 2 ) for 3 weeks to induce PH. EC proliferation, apoptosis, cell junction assay, Western blotting, QRT-PCR, RNA-sequencing analysis, and luciferase assays were performed to understand the molecular mechanisms of SOX17 deficiency and mutation in ECs. siRNA and inhibitors were used to determine the involvement of E2F1/BRD4 signaling in SOX17 deficiency ECs. Results: Sox17iCKO mice developed spontaneous mild PH and exaggerated hypoxia-induced PH evidenced by the increase of RVSP and RV hypertrophy compared to WT mice. SOX17 knockdown in human PVECs induced cell proliferation, anti-apoptosis, and impaired cell integrity. SOX17 knockdown reduced BMPR2 signaling. SOX17 knockdown and mutations at the HMG domain lost transcriptional activities and its ability to repress -catenin. RNA-seq analysis demonstrated enrichment of cell cycle pathway after the loss of SOX17 in PVECs. iRegulon analysis revealed the involvement of transcriptional factor E2F1. siRNA-mediated E2F1 knockdown normalized SOX17 deficiency-induced PVECs dysfunction. Knockdown SOX17 significantly upregulated E2F1 promoter activity, which was dependent on the binding site in the E2F1 promoter by luciferase and mutagenesis assay. E2F1 or BRD4 inhibitors attenuated SOX17 deficiency-induced PH in mice. Conclusions: Our study demonstrated that endothelial loss of SOX17 induces PH in mice. Pharmacological inhibition of E2F1/BRD4 signaling attenuated PH development in Sox17iCKO mice.

SOX7 Suppresses Endothelial-to-mesenchymal Transitions by Enhancing VE-cadherin Expression During Outflow Tract Development.

SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome‐Mediated Autocrine Manner

The Transcription Factor Sox7 Modulates Endocardiac Cushion Formation Contributed to Atrioventricular Septal Defect Through Wnt4/Bmp2 Signaling

SOX7 loss-of-function variation as a cause of familial congenital heart disease

Novel role of sex-determining region Y-box 7 (SOX7) in tumor biology and cardiovascular developmental biology

Three Rare Variants of SOX7 Impairing Its Interaction with GATA4 May Be a Predisposing Factor to Complete AVSD

Sox7-positive endothelial progenitors establish coronary arteries and govern ventricular compaction

Sox7 is Regulated by ETV2 During Cardiovascular Development.

Distinct roles of SOX9 in self-renewal of progenitors and mesenchymal transition of the endothelium

Predisposition to Atrioventricular Septal Defects May Be Caused by SOX7 Variants That Impair Interaction with GATA4

Identification of FOXH1 Mutations in Patients with Sporadic Conotruncal Heart Defect

Msx1 and Msx2 Regulate Survival of Secondary Heart Field Precursors and Post-Migratory Proliferation of Cardiac Neural Crest in the Outflow Tract

SOX17 Prevents Endothelial-Mesenchymal Transition of Pulmonary Arterial Endothelial Cells in Pulmonary Hypertension through Mediating TGF-β/Smad2/3 Signaling

SOX7: from a developmental regulator to an emerging tumor suppressor.

MESP2variants Contribute to Conotruncal Heart Defects by Inhibiting Cardiac Neural Crest Cell Proliferation

LARP7 Suppresses Endothelial-to-Mesenchymal Transition by Coupling with TRIM28

Variants in a Cis-Regulatory Element of TBX1 in Conotruncal Heart Defect Patients Impair GATA6-mediated Transactivation.

SOX7 Modulates the Progression of Hepatoblastoma Through the Regulation of Wnt/β-catenin Signaling Pathway.

Abstract 13304: Sox17 Deficiency Induces Pulmonary Hypertension Through E2F1/BRD4 Signaling

Abstract 14257: Endothelial SOX17 Deficiency Induces Pulmonary Arterial Hypertension

Reduced dosage of β-catenin provides significant rescue of cardiac outflow tract anomalies in a Tbx1 conditional null mouse model of 22q11.2 deletion syndrome